Novartis' Zelnorm For Chronic Constipation Recommended With Restrictions

Patients over the age of 65 and males should be excluded from treatment with Zelnorm (tegaserod) for chronic constipation, FDA gastrointestinal advisory committee says. Concerns about the risk of ischemic colitis and severe diarrhea, and lack of efficacy, in older patients were cited by committee members.